November 25, 2015
LAS VEGAS — A single dose of a novel topical bimatoprost ocular insert demonstrated sustained IOP reduction in patients with glaucoma and ocular hypertension at 6 months, according to phase 2 study results presented here.
“Despite highly effective topical treatments, half of our patients stop using their drops by 1 year, and among those who do continue to use their drops, many of them have difficulty using them properly. ... There is a pressing need for sustained patient behavior independent delivery of glaucoma medications to prevent blindness,” James D. Brandt, MD, said at the American Academy of Ophthalmology annual meeting.